Announcement
Report on ordinary general meeting held in NeuroSearch A/S
Pursuant to announcement, the ordinary general meeting of NeuroSearch A/S was
held today Wednesday 25 April 2007.
The Chairman of the Board presented the oral report. The annual report 2006 and
the Board of Directors' proposal to carry the 2006 result forward to next year
were adopted by the general meeting.
Asger Aamund, Marianne Philip, Allan Andersen, Torbjørn Bjerke and Jørgen Buus
Lassen were re-elected as members of the board.
PricewaterhouseCoopers was re-elected as NeuroSearch's sole auditor.
The Board of Directors was given authorization until the next general meeting to
acquire own shares by the general meeting.
The following suggested amendments to the Articles of Association were agreed
upon by the general meeting with more than two third majority but could not be
finally adopted as less than half of the share capital was represented at the
general meeting: article 5 regarding an authorisation to the Board of Directors
to increase the Company's share capital, article 5a regarding an authorisation
to the Board of Directors to issue warrants and article 10 regarding form and
notice of general meetings to be updated on the basis of the current Danish
Companies Act.
An extraordinary general meeting will therefore be held on 14 May 2007 at 10 am
where the same amendments to the Articles of Association will be presented for
adoption.
Asger Aamund
Chairman of the Board
Contact person: Flemming Pedersen, CEO, telephone: +45 2148 0118
NeuroSearch is a Scandinavian biopharmaceutical company listed on the Copenhagen
Stock Exchange (NEUR). Our core business covers the development of novel drugs,
based on a broad and well-established drug discovery platform focusing on ion
channels and diseases of the central nervous system (CNS). A substantial part of
the company's activities are partner financed through a broad alliance with
GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas.
Eight drug programmes are in clinical development: ACR16 for the treatment of
Huntington's disease (under preparation for Phase III), tesofensine for the
treatment of obesity/type 2 diabetes (Phase II), NS2359 for the treatment of
depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 for
the treatment of epilepsy and pain (Phase II), ABT-894 for the treatment of ADHD
(Phase II) and neuropathic pain (Phase I) in partnership with Abbott, ACR16 for
the treatment of schizophrenia (Phase I) in partnership with Astellas, and
ACR325 for the treatment of psychoses and bipolar disorder (Phase I). In
addition, NeuroSearch has a broad portfolio of preclinical drug candidates and
has equity interests in several biotech companies.
